Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

915.01 +13.21 (+1.46%)
Official Closing Price Updated: 6:30 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,032,581
Open 898.37
Bid (Size) 911.59 (2)
Ask (Size) 916.62 (1)
Prev. Close 901.80
Today's Range 896.60 - 922.43
52wk Range 711.40 - 972.53
Shares Outstanding N/A
Dividend Yield 0.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target
Eli Lilly is investing over $50 billion in U.S. manufacturing, adding four new sites to boost domestic medicine production and create thousands of jobs. 
Via Benzinga

Performance

YTD
+17.60%
+17.60%
1 Month
+13.22%
+13.22%
3 Month
+15.92%
+15.92%
6 Month
-4.14%
-4.14%
1 Year
+18.54%
+18.54%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum
Via AB Newswire
Topics Artificial Intelligence Derivatives Intellectual Property
Exposures Artificial Intelligence Derivatives Intellectual Property
Market Monitor February 25th
Via Chartmill
Why Eli Lilly Stock Popped Today
Via The Motley Fool
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Why Organovo (ONVO) Stock Is Skyrocketing
Via Benzinga
Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses
Via Benzinga
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Via StockStory
Elanco (NYSE:ELAN) Surprises With Q4 Sales
Via StockStory
Unlocking the high Growth Potential of NYSE:LLY.
Via Chartmill
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Via StockStory
Elanco (ELAN) Q4 Earnings Report Preview: What To Look For
Via StockStory
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Via StockStory
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
Via Benzinga
Topics Government
Exposures Political
3 Magnificent Growth Stocks to Buy Right Now
Via The Motley Fool
In Flight Dining
Via Talk Markets
Topics Stocks / Equities
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly (LLY): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Stocks
Exposures US Equities
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
Via Stocktwits
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Via Talk Markets
Topics Stocks / Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.